

# NeuTec Pharma plc

14 February 2002

## Publication of AIM Admission Document and Pricing

*NeuTec* Pharma plc (“*NeuTec*”), a biopharmaceutical company which focuses on developing a portfolio of antibody-based therapeutic products designed to treat life-threatening infections, has today published its Admission Document in relation to the proposed admission of its shares to the Alternative Investment Market of the London Stock Exchange (“AIM”) and a placing of new ordinary shares (the “Placing”) with institutional investors.

Under the Placing 7,150,000 new ordinary shares in *NeuTec* are being placed at a price of 150 pence per ordinary share (the “Placing Price”). No existing shareholders are selling shares in the Placing such that the directors and the University of Manchester will retain significant equity holdings post-admission. The Placing will raise approximately £10.0 million net of expenses for *NeuTec*. At the Placing Price, *NeuTec* is valued at £35.4 million.

Dealings in *NeuTec*’s shares on AIM are expected to commence on 20 February 2002.

James Burnie, Chief Executive of *NeuTec*, commented:

“We have been delighted by the response we have received from institutional investors in recent weeks.

“We believe that *NeuTec*’s products have the potential to significantly reduce the spread of hospital-acquired antibiotic-resistant infections that kill thousands of people every year across the world.

“Our task now is to realise that potential and to create value for our existing and new shareholders whilst delivering solutions for what is a significant, unmet clinical need.

“We have received great support from the University of Manchester and our other existing shareholders during our first five years, and we now look forward to the next stage in *NeuTec*’s development as a quoted company.”

Hoare Govett Limited is acting as underwriter, nominated adviser and broker to *NeuTec*.

**- Ends -**

*(Contact details attached)*

Contd./ 2

**NeuTec Pharma plc: Publication of AIM Admission Document and Pricing (contd./)**

- 2 -

For further information, please contact:

**NeuTec Pharma plc** via Hogarth Partnership (see below)  
Professor James Burnie, Chief Executive

**Hoare Govett Limited** 020 7678 8000  
Justin Jones  
Andrew Chapman

**Hogarth Partnership** 020 7357 9477  
John Olsen  
Georgina Briscoe

*The directors of NeuTec Pharma plc accept responsibility for the information contained in this announcement. The contents of this announcement have been approved by Hoare Govett Limited solely for the purposes of section 21 of the Financial Services and Markets Act 2000. Hoare Govett Limited, which is authorised in the United Kingdom under the Financial Services and Markets Act 2000, is acting for NeuTec Pharma plc and for no-one else in connection with the Placing and will not be responsible to anyone other than NeuTec Pharma plc for providing the protections afforded to clients of Hoare Govett Limited or for providing advice in relation to the Placing.*

*This announcement does not constitute, or form part of, an offer or any solicitation of an offer, for securities or any purchase of, or application for, securities. In particular, this announcement is not an offer of securities for sale in the United States, Canada, Australia or Japan. The securities of the Company are not being registered under the US Securities Act of 1933, as amended (the "Securities Act") or under the applicable securities laws of Canada, Australia or Japan and, subject to certain exceptions, may not be offered or sold in the United States (as such term is defined in Regulation S under the Securities Act), Canada, Australia or Japan. No money, securities or other consideration is being solicited by this announcement or the information it contains in any jurisdiction in which such offer is not authorised or to any person to whom it is unlawful to make such an offer or invitation, and if sent in response to this announcement or the information it contains will not be accepted.*